{
  "id": "6025f7dc1cb411341a0000bd",
  "type": "summary",
  "question": "What is the mechanisms of action of pexidartinib?",
  "ideal_answer": "Pexidartinib is small-molecule tyrosine kinase inhibitor that has strong selectivity against colony-stimulating factor 1 receptor.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31229240",
    "http://www.ncbi.nlm.nih.gov/pubmed/31420495",
    "http://www.ncbi.nlm.nih.gov/pubmed/30926949",
    "http://www.ncbi.nlm.nih.gov/pubmed/32440095",
    "http://www.ncbi.nlm.nih.gov/pubmed/31862477",
    "http://www.ncbi.nlm.nih.gov/pubmed/30825104",
    "http://www.ncbi.nlm.nih.gov/pubmed/32535390",
    "http://www.ncbi.nlm.nih.gov/pubmed/31240240",
    "http://www.ncbi.nlm.nih.gov/pubmed/31602563",
    "http://www.ncbi.nlm.nih.gov/pubmed/31258629",
    "http://www.ncbi.nlm.nih.gov/pubmed/31213500",
    "http://www.ncbi.nlm.nih.gov/pubmed/33143617",
    "http://www.ncbi.nlm.nih.gov/pubmed/32251854",
    "http://www.ncbi.nlm.nih.gov/pubmed/31848580",
    "http://www.ncbi.nlm.nih.gov/pubmed/32306101",
    "http://www.ncbi.nlm.nih.gov/pubmed/32943455"
  ],
  "snippets": [
    {
      "text": "A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30825104",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase inhibitor, has strong selectivity against colony-stimulating factor 1 receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30825104",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30926949",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Colony-stimulating factor 1 (CSF1) controls macrophage differentiation, and here we sought to determine the effect of a CSF1 receptor inhibitor, PLX3397, on adipose tissue macrophage levels and understand the impact on glucose homeostasis in mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30926949",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To address the role of these cells in disease pathogenesis, we depleted microglia from R6/2 mice, a rapidly progressing model of Huntington's disease marked by behavioural impairment, mutant huntingtin (mHTT) accumulation, and early death, through colony-stimulating factor 1 receptor inhibition (CSF1Ri) with pexidartinib (PLX3397) for the duration of disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31848580",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pexidartinib is a CSF1R antagonist that is prescribed for the treatment of tenosynovial giant cell tumors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31862477",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Methods: Female MMTV-PyMT mice were treated with pexidartinib, a colony-stimulating factor 1 receptor (CSF1R) inhibitor, to reduce TAM density. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31420495",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ODS: This was an investigator-initiated, phase I, dose escalation study of the MEK inhibitor binimetinib combined with pexidartinib, a potent inhibitor of CSF1R, KIT, and FLT3, in patients with advanced or metastatic GIST who progressed on imatinib. The",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31213500",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We evaluated the recently FDA-approved CSF1R inhibitor Pexidartinib (PLX3397) in OSA cell lines in vitro and in vivo in cell line and patient-derived xenografts.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32251854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pexidartinib (TURALIO\u2122) is an orally administered small molecule tyrosine kinase inhibitor with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto-oncogene receptor tyrosine kinase (KIT) and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation (FLT3-ITD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31602563",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Pexidartinib (PLX3397) is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor under clinical evaluation for potential CNS tumor treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32306101",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "amics of pexidartinib. Special attention is given to various reported clinical trials of pexidartinib.METHODS: A comprehensive literature search was conducted in the relevant databases to identify studies published in this field during recent years Conclusion: Pexidartinib acts by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway which leads to inhibition of the cell lines proliferation and promotes the autophosphorylation process ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33143617",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " tumors. Pexidartinib, an oral inhibitor of tyrosine kinases including colony stimulating factor 1 receptor (CSF-1R), KIT, and FLT3, is FDA approved in adults with tenosynovial giant ce",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32943455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Pexidartinib (PLX3397) is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor under clinical evaluation for potential CNS tumor t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32306101",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32440095",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "MD simulation indicated (-)-kusunokinin and pexidartinib (P31, a specific CSF1R binding compound) shared some extents of functional similarity in which (-)-kusunokinin bound CSF1R at the juxtamembrane (JM) region with aromatic amino acids similar to pexidartinib using \u03c0-\u03c0 interaction, as well as hydrogen bond. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32535390",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Surgery is standard with no approved systemic therapy. We aimed to evaluate pexidartinib, a CSF1 receptor inhibitor, in patients with TGCT to provide them with a viable systemic treatment option, especially in cases that are not amenable to surgical resection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31229240",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31258629",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Purpose: To evaluate the safety, recommended phase\u2009II dose (RP2D) and efficacy of pexidartinib, a colony stimulating factor receptor\u20091 (CSF-1R) inhibitor, in combination with weekly paclitaxel in patients with advanced solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31258629",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-Hodgkin's lymphoma, and glioblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31240240",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}